Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study

W. C. Koller, G. A. Block, J. E. Ahlskog, S. Ahrens, J. M. Cedarbaum, G. Cyhan, C. G. Goetz, P. A. LeWitt, C. Liss, L. McLean, H. Moses, M. D. Muenter, P. Nausieda, J. Sanchez-Ramos, S. Reich, C. Singer, S. Stellar, W. J. Weiner

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458 [hydroxypropyl methylcellulose/lactose matrix (HPMC)], a sustained release formulation of a novel naphthoxazine compound with selective D-2 dopamine receptor agonism. Patients were previously untreated with dopaminergic drugs. Efficacy was assessed by clinical rating scales and by patient self-evaluation. MK-458 (HPMC) caused a significant decrease in most parkinsonian symptoms. Though disability rating scores were lowered by the drug, the scores did not differ significantly from placebo. However, statistically significant improvement occurred with MK-458 (HPMC) on both the physician and the patient global assessments. Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo. MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use. Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)322-329
Number of pages8
JournalClinical neuropharmacology
Volume14
Issue number4
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Keywords

  • MK-458
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study'. Together they form a unique fingerprint.

  • Cite this

    Koller, W. C., Block, G. A., Ahlskog, J. E., Ahrens, S., Cedarbaum, J. M., Cyhan, G., Goetz, C. G., LeWitt, P. A., Liss, C., McLean, L., Moses, H., Muenter, M. D., Nausieda, P., Sanchez-Ramos, J., Reich, S., Singer, C., Stellar, S., & Weiner, W. J. (1991). Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study. Clinical neuropharmacology, 14(4), 322-329. https://doi.org/10.1097/00002826-199108000-00004